lifestyle.emphas.is

Author: Cue Biopharma, Inc.

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

April 30, 2026
Cue Biopharma Announces $30 Million Private Placement

April 30, 2026
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

April 30, 2026
Cue Biopharma Announces 1-for-30 Reverse Stock Split

April 22, 2026
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

April 15, 2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

April 8, 2026
Cue Biopharma Announces CEO Transition

March 27, 2026
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

March 26, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

March 16, 2026
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

March 9, 2026